[go: up one dir, main page]

IL99521A0 - Nasal pharmaceutical composition - Google Patents

Nasal pharmaceutical composition

Info

Publication number
IL99521A0
IL99521A0 IL99521A IL9952191A IL99521A0 IL 99521 A0 IL99521 A0 IL 99521A0 IL 99521 A IL99521 A IL 99521A IL 9952191 A IL9952191 A IL 9952191A IL 99521 A0 IL99521 A0 IL 99521A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
nasal pharmaceutical
nasal
composition
pharmaceutical
Prior art date
Application number
IL99521A
Other languages
English (en)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL99521A0 publication Critical patent/IL99521A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL99521A 1990-09-20 1991-09-19 Nasal pharmaceutical composition IL99521A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020544A GB9020544D0 (en) 1990-09-20 1990-09-20 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
IL99521A0 true IL99521A0 (en) 1992-08-18

Family

ID=10682494

Family Applications (1)

Application Number Title Priority Date Filing Date
IL99521A IL99521A0 (en) 1990-09-20 1991-09-19 Nasal pharmaceutical composition

Country Status (21)

Country Link
US (1) US5578567A (es)
EP (2) EP0672682A1 (es)
JP (1) JPH04247034A (es)
KR (1) KR920006003A (es)
AT (1) ATA189691A (es)
AU (1) AU8464791A (es)
CA (1) CA2051721A1 (es)
CH (1) CH683749A5 (es)
CS (1) CS285491A3 (es)
DE (1) DE4131232A1 (es)
FI (1) FI914398A (es)
FR (2) FR2666987A1 (es)
GB (2) GB9020544D0 (es)
IE (1) IE913296A1 (es)
IL (1) IL99521A0 (es)
IT (1) IT1255258B (es)
LU (1) LU88006A1 (es)
MX (1) MX9101175A (es)
NO (1) NO913668D0 (es)
PT (1) PT99007A (es)
ZA (1) ZA917528B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3090353B2 (ja) * 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
WO1993011785A1 (en) * 1991-12-09 1993-06-24 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
DE4203040A1 (de) * 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel
CA2094217A1 (en) * 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
EP0806945B1 (en) * 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
US5908400A (en) * 1996-06-20 1999-06-01 Hisamitsu Pharmaceutical Co., Inc. Device structure for iontophoresis
TW505654B (en) * 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1721617A3 (en) * 1997-07-22 2008-05-28 Chugai Seiyaku Kabushiki Kaisha Dental therapeutics containing parathyroid hormone
AU745122B2 (en) 1997-07-30 2002-03-14 Emory University Novel bone mineralization proteins, DNA, vectors, expression systems
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
MY120063A (en) † 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
DE19756314C2 (de) * 1997-12-12 2000-06-29 Roland Bodmeier Zubereitung mit verlängerter Verweildauer am Applikationsort
JPH11246439A (ja) * 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
EP1079801A1 (en) * 1998-05-20 2001-03-07 Highchem Company., Ltd. A pharmaceutical formulation for nasal administration
CN1065141C (zh) * 1998-05-20 2001-05-02 北京金源东和化学有限责任公司 通过鼻粘膜给药的药物制剂
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
WO2000012136A1 (fr) * 1998-08-26 2000-03-09 Teijin Limited Compositions en poudre s'administrant par voie nasale
JP2000239187A (ja) * 1999-02-22 2000-09-05 Dotto:Kk 経鼻吸収用組成物
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
ATE274955T1 (de) * 1999-05-03 2004-09-15 Battelle Memorial Institute Arzneizusammensetzungen zur aerosolbildung und zu inhalationszwecken
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
ES2166278B2 (es) * 1999-09-14 2003-06-16 Univ Madrid Complutense Procedimiento de preparacion de polvos nasales por atomizacion utilizando excipientes insolubles y absorbentes como promotores de absorcion nasal.
DE60142043D1 (de) * 2000-04-03 2010-06-17 Battelle Memorial Inst Columbu Ausgabevorrichtungen und flüssigformulierungen
CN100518819C (zh) 2000-06-30 2009-07-29 阿斯比奥制药株式会社 含有人甲状旁腺激素的药物成分及含有该成分的用于鼻内给药的药物组合物
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
DE10120200B4 (de) * 2001-04-24 2005-12-22 Infood Gmbh Schnupfpulver als Schnupftabakersatz
CN100522245C (zh) * 2002-05-23 2009-08-05 Umd公司 用于穿粘膜的药物输送和冷冻保护的组合物
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003286472A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
AU2005247369A1 (en) 2004-05-10 2005-12-08 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US7906137B2 (en) * 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
CA2573309A1 (en) * 2004-07-14 2006-01-19 Chugai Seiyaku Kabushiki Kaisha Transmucosal administration agent containing pth
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
BRPI0608309A2 (pt) * 2005-02-23 2009-12-08 Alza Corp administração intranasal de agentes ativos ao sistema nervoso central
US20090042790A1 (en) * 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
EP1931374A2 (en) * 2005-10-06 2008-06-18 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
JP2009515535A (ja) 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
WO2008065144A2 (en) * 2006-11-29 2008-06-05 Novartis Ag Galenic formulations of organic compounds
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
KR20130010462A (ko) * 2010-03-19 2013-01-28 다이이찌 산쿄 가부시키가이샤 경비 투여용 조성물 및 그 제조 방법
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
US11124479B2 (en) 2017-07-14 2021-09-21 New York University Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization
US10500197B2 (en) 2017-07-18 2019-12-10 New York University Use of oligopyridylamides to inhibit mutant p53 amyloid formation and restore its tumor suppressor function
WO2021229835A1 (ja) * 2020-05-11 2021-11-18 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する安定な液状医薬製剤
AU2022209699A1 (en) * 2021-01-21 2023-07-13 Nbo Pharma Inc. Intranasal formulations and delivery of somatostatin mimetics and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JPS63243033A (ja) * 1987-03-31 1988-10-07 Toyo Jozo Co Ltd 経鼻投与組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
CA1336401C (en) * 1987-10-15 1995-07-25 Brian H. Vickery Intranasal administration of polypeptides in powdered form
GB2212062B (en) * 1987-11-13 1991-07-17 Isf Spa Pharmaceutical compositions containing a calcitonin and a glycyrrhizinate ab- sorption enhancer
JPH0242027A (ja) * 1988-08-02 1990-02-13 Minofuaagen Seiyaku Honpo:Goushi 経粘膜吸収促進剤及びこれを用いた経鼻投与剤
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
CA2047686C (en) * 1989-03-08 2000-09-05 Joseph Larner Dietary supplement for insulin-resistant diabetics
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment

Also Published As

Publication number Publication date
AU8464791A (en) 1992-03-26
IT1255258B (it) 1995-10-20
LU88006A1 (fr) 1993-04-15
GB2248550A (en) 1992-04-15
MX9101175A (es) 1992-05-04
JPH04247034A (ja) 1992-09-03
FI914398A (fi) 1992-03-21
FR2666987A1 (fr) 1992-03-27
IE913296A1 (en) 1992-02-25
PT99007A (pt) 1992-08-31
ITRM910696A0 (it) 1991-09-18
KR920006003A (ko) 1992-04-27
EP0490806A2 (en) 1992-06-17
CS285491A3 (en) 1992-04-15
GB9020544D0 (en) 1990-10-31
GB2248550B (en) 1995-04-05
GB9120024D0 (en) 1991-11-06
ATA189691A (de) 1997-10-15
FI914398A0 (fi) 1991-09-18
DE4131232A1 (de) 1992-03-26
FR2681326A1 (fr) 1993-03-19
EP0490806A3 (en) 1992-09-23
EP0672682A1 (en) 1995-09-20
FR2681326B1 (fr) 1995-06-16
CH683749A5 (de) 1994-05-13
ZA917528B (en) 1993-03-22
CA2051721A1 (en) 1992-03-21
ITRM910696A1 (it) 1993-03-18
US5578567A (en) 1996-11-26
NO913668D0 (no) 1991-09-18

Similar Documents

Publication Publication Date Title
GB9120024D0 (en) Nasal pharmaceutical composition
AP9200356A0 (en) Pharmaceutical composition
ZA915861B (en) Pharmaceutical compositions
GB9111314D0 (en) Pharmaceutical compositions
GB9122083D0 (en) Pharmaceutical compositions
ZA915677B (en) Solid pharmaceutical composition
GB9026080D0 (en) Pharmaceutical compositions
GB9003185D0 (en) Pharmaceutical compositions
ZA917596B (en) Pharmaceutical compositions
GB9115156D0 (en) Pharmaceutical compositions
ZA915450B (en) Pharmaceutical composition
GB9206151D0 (en) Nasal pharmaceutical composition
GB9115169D0 (en) Pharmaceutical compositions
GB9005599D0 (en) Pharmaceutical composition
GB9023953D0 (en) Pharmaceutical composition
GB9027089D0 (en) Pharmaceutical composition
GB9018194D0 (en) Pharmaceutical composition
ZA918388B (en) Pharmaceutical composition
GB9011541D0 (en) Pharmaceutical composition
GB9015988D0 (en) Pharmaceutical composition
GB9016176D0 (en) Pharmaceutical composition
GB9016191D0 (en) Pharmaceutical composition
GB9002350D0 (en) Pharmaceutical composition
GB9021541D0 (en) Pharmaceutical composition
ZA911438B (en) Pharmaceutical composition